Cysteinyl leukotrienes (CysLTs), previously known as the slow reacting substance of anaphylaxis, are produced predominantly by myeloid cells associated with inflammatory responses. They are the most potent bronchoconstrictors known and also have pro-inflammatory effects, making them important mediators in the pathophysiology of Human asthma. CysLTs have also been implicated in a variety of other diseases, such as allergic rhinitis, inflammatory bowel disease and psoriasis. Cysteinyl leukotriene receptor 1, a Chemoattractant Receptor, is detected in spleen, peripheral blood leukocytes, and lung smooth muscle (Lynch et al., 1999). It binds cysteinyl leukotrienes, which are neutrophil chemoattractants with potent proinflammatory action. Leukotrienes mediate many features of bronchial asthma such as edema, bronchial constriction, and hyperreactivity (Bisgaard et al., 2000). Selective CysLT1 antagonists are used to treat asthma.
Applications:
Suitable for use in Immunohistochemistry. Other applications not tested.
Recommended Dilution:
Immunohistochemistry (paraffin): 6-14ug/ml
Optimal dilutions to be determined by the researcher.
Positive Control:
Human nasal mucosa, allergic rhinitis, eosinophils
Storage and Stability:
May be stored at 4 degrees C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Quick Search
Products 
